Lasofoxifene Tartrate CAS 190791-29-8 Chiral Purity ≥99.0% Purity ≥98.0% (HPLC) API High Purity

Kufotokozera Kwachidule:

Dzina la mankhwala: Lasofoxifene tartrate

CAS: 190791-29-8

Maonekedwe: Ufa Woyera mpaka Woyera

Chiral Purity: ≥99.0%Kuyera: ≥98.0% (HPLC)

Pochiza Postmenopausal Osteoporosis

API High Quality, Commercial Production

Inquiry: alvin@ruifuchem.com

Titumizireni imelo

Tsatanetsatane wa Zamalonda

Zogwirizana nazo

Zolemba Zamalonda

Kufotokozera:

Zopanga Zopanga Zokhala ndi Chiyero Chapamwamba ndi Ubwino Wokhazikika
Dzina la mankhwala: Lasofoxifene tartrate
CAS: 190791-29-8
Lasofoxifene Tartrate (CAS: 190791-29-8) pochiza Postmenopausal Osteoporosis

Chemical Properties:

Dzina la Chemical	Lasofoxifene tartrate
Mawu ofanana ndi mawu	(5R,6S) -5,6,7,8-Tetrahydro-6-phenyl-5-[4-[2-(1-pyrrolidinyl) ethoxy]phenyl] -2-naphthalenol Tartrate Oporia
Nambala ya CAS	190791-29-8
Nambala ya CAT	RF-API20
Stock Status	Mu Stock, Kupanga Kufikira Mazana a Kilogram
Molecular Formula	C28H31NO2.ClH
Kulemera kwa Maselo	450.019
Mtundu	Ruifu Chemical

Zofotokozera:

Kanthu	Zofotokozera
Maonekedwe	Ufa Woyera mpaka Woyera
Chinyezi (KF)	≤0.50%
Zitsulo Zolemera	≤20ppm
Chiral Purity	≥99.0%
Kuyera / Kusanthula Njira	≥98.0% (HPLC)
Kutaya pa Kuyanika	≤0.50%
Zotsalira pa Ignition	≤0.50%
Test Standard	Chinese Pharmacopoeia (CP);Enterprise Standard
Kugwiritsa ntchito	Zomwe Zimagwira Ntchito Zamankhwala (API);Postmenopausal Osteoporosis

Phukusi & Kusungira:

Phukusi: Botolo, Aluminiyamu zojambulazo thumba, makatoni ng'oma, 25kg / Drum, kapena malinga ndi zofuna za kasitomala.

Mkhalidwe Wosungira:Sungani muzitsulo zosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala, chinyezi ndi tizilombo towononga.

Ubwino:

FAQ:

Ntchito:

Shanghai Ruifu Chemical Co., Ltd. ndi omwe amapanga komanso amapereka Lasofoxifene Tartrate (CAS: 190791-29-8) yokhala ndipamwamba kwambiri.
Lasofoxifene Tartrate ndi m'badwo wachitatu, wopanda steroidal selective estrogen receptor modulator (SERM).Imasankha ERalpha yaumunthu ndi mtengo wa IC50 wa 1.5 nM ndipo imalepheretsa kutayika kwa mafupa mu makoswe ovariectomized.M'maphunziro azachipatala a postmenopausal osteoporosis, 0.5 mg/tsiku lasofoxifene idalumikizidwa ndi kuchepetsedwa kwa kuopsa kwa fractures za nonvertebral ndi vertebral, khansa ya m'mawere ya ER-positive, matenda a mtima, ndi sitiroko koma chiopsezo chowonjezeka cha zochitika za venous thromboembolic.Lasofoxifene yasonyezedwanso kuti imakhala ngati agonist inverse pa CB2 cannabinoid receptor, kusonyeza kuthekera kwake kubwezeretsedwanso ngati mankhwala owonetsera momwe CB2 ndi chandamale.